Pharmacotherapy of uveitis

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 7, 2010, Pages 1135-1146

  Lee, Frank F ^a   Foster, Charles Stephen ^a  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

Author keywords

Alkylating agents; Antimetabolites; Biologic response modulators; Calcineurin inhibitors; Corticosteroids; Inflammation; Iritis; NSAIDS; Ophthalmology; Uveitis

Indexed keywords

ATROPINE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPENTOLATE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DEXAMETHASONE SODIUM PHOSPHATE; DIFLUPREDNATE; ETANERCEPT; FLUOCINOLONE ACETONIDE; FLUOROMETHOLONE; HOMATROPINE; HYDROCORTISONE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENYLEPHRINE; PREDNISOLONE ACETATE; PREDNISOLONE SODIUM PHOSPHATE; PREDNISONE; RAPAMYCIN; RESTATIS; SCOPOLAMINE BROMIDE; TACROLIMUS; TROPICAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOCLOSPORIN;

ADRENAL CORTEX INSUFFICIENCY; ANTIINFLAMMATORY ACTIVITY; BONE MARROW SUPPRESSION; CAPILLARY RESISTANCE; CATARACT; CLINICAL TRIAL; COMPETITIVE INHIBITION; CORTICOSTEROID THERAPY; CYTOPENIA; DIABETES MELLITUS; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG TREATMENT FAILURE; FATIGUE; FEMALE STERILITY; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERTROPHY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; IMPLANT; INFECTION; INJECTION SITE REACTION; INSOMNIA; INTRAOCULAR PRESSURE; IRRITABILITY; LIVER TOXICITY; LOW DRUG DOSE; MALE STERILITY; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NONHUMAN; OSTEOPOROSIS; PATIENT MONITORING; PNEUMONIA; RECOMMENDED DRUG DOSE; REMISSION; REVIEW; SECONDARY GLAUCOMA; SEIZURE; SEPSIS; SIDE EFFECT; SKIN ATROPHY; STRIA; TOPICAL TREATMENT; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; UVEITIS; WEIGHT GAIN;

ANIMALS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYDRIATICS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; UVEITIS;

EID: 77951285574     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003713534     Document Type: Review

References (91)

1. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996;80(9):844-848 (Pubitemid 26345317)
2. Vadot E. Epidemiology of intermediate uveitis: a prospective study in Savoy. Dev Ophthalmol 1992;23:33-34
3. Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140(3):509-516
4. Melton NR, Thomas RK. Medical management of anterior uveitis. Optom Clin 1991;1(4):71-78
5. American Academy of Ophthalmology. Basic and Clinical Science Course; Fundamentals and Principles of Ophthalmology, Section 2 2007 -- 2008
6. Munoz-Fernandez S, Hidalgo V, Fernández-Melón J, et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 2003;30(6):1277-1279 (Pubitemid 36666354)
7. Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Banares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 2000;14(Pt 3A):340-343 (Pubitemid 30479708)
8. Samiy N, Foster CS. The role of nonsteroidal antiinflammatory drugs in ocular inflammation. Int Ophthalmol Clin 1996;36(1):195-206 (Pubitemid 26116954)
9. Tripathi RC, Parapuram SK, Tripathi BJ, et al. Corticosteroids and glaucoma risk. Drugs Aging 1999;15(6):439-450
10. Novack GD, Howes J, Crockett RS, Sherwood MB. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma 1998;7(4):266-269 (Pubitemid 29149820)
11. Sasamoto Y, Ohno S, Matsuda H. Studies on corticosteroid therapy in Vogt-Koyanagi-Harada disease. Ophthalmologica 1990;201(3):162-167 (Pubitemid 20343836)
12. Wakefield D, McCluskey P, Penny R. Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease. Arch Ophthalmol 1986;104(6):847-851 (Pubitemid 16114932)
13. Niewoehner CB, Niewoehner DE. Steroid-induced osteoporosis. Are your asthmatic patients at risk? Postgrad Med 1999;105:79-83, 87-88, 91
14. Ferrante P, Ramsey A, Bunce C, Lightman S. Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin Exp Ophthalmol 2004;32(6):563-568 (Pubitemid 40074099)
15. Riordan-Eva P, Lightman S. Orbital floor steroid injections in the treatment of uveitis. Eye 1994;8(Pt 1):66-69 (Pubitemid 24141230)
16. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001;108(4):765-772 (Pubitemid 32238474)
17. Degenring RF, Jonas JB. Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis. Br J Ophthalmol 2003;87(3):361 (Pubitemid 36307916)
18. Jaffe GJ, McCallum RM, Branchaud B, et al. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 2005;112(7):1192-1198 (Pubitemid 40916923)
19. Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol 2007;125(11):1478-1485 (Pubitemid 350106679)
20. Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009;339:b2480
21. Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 2005;13(5):335-351
22. Wong VG. Methotrexate treatment of uveal disease. Am J Med Sci 1966;251(2):239-241
23. Bom S, Zamiri P, Lightman S. Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol Inflamm 2001;9(1):35-40 (Pubitemid 32234164)
24. Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001;108(6):1134-1139 (Pubitemid 32500033)
25. Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol Suppl 1985;12(Suppl 12):35-39 (Pubitemid 16082378)
26. Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008;58(1):73-81
27. Spina CA. Azathioprine as an immune modulating drug: clinical applications. Clin Immunol Allergy 1984;4:415-446
28. Chan GL, Canafax DM, Johnson CA. The therapeutic use of azathioprine in renal transplantation. Pharmacotherapy 1987;7(5):165-177 (Pubitemid 18001594)
29. Hemady RK, Baer JC, Foster CS. Immunosuppressive drugs in the management of progressive, corticosteroid-resistant uveitis associated with juvenile rheumatoid arthritis. Int Ophthalmol Clin 1992;32(1):241-252
30. Newell FW, Krill AE. Treatment of uveitis with azathioprine (Imuran). Trans Ophthalmol Soc UK 1967;87:499-511
31. Andrasch RH, Pirofsky B, Burns RP. Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol 1978;96(2):247-251 (Pubitemid 8297325)
32. Mathews JD, Crawford BA, Bignell JL, Mackay IR. Azathioprine in active chronic iridocyclitis. A double-blind controlled trial. Br J Ophthalmol 1969;53(5):327-330
33. Singh G, Fries JF, Spitz P, Williams CA. Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. Arthritis Rheum 1989;32(7):837-843 (Pubitemid 19181005)
34. McLeod HL, Coulthard S, Thomas AE, et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 1999;105(3):696-700 (Pubitemid 29277028)
35. Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999;93(3):198-208
36. Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001;44(9):1984-1992 (Pubitemid 33644039)
37. Robertson SM, Lang LS. Leflunomide: inhibition of S-antigen induced autoimmune uveitis in Lewis rats. Agents Actions 1994;42(3-4):167-172 (Pubitemid 2162090)
38. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130(4):492-513
39. Baltatzis S, Tufail F, Yu EN, et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 2003;110(5):1061-1065 (Pubitemid 36560514)
40. Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 2005;13(5):335-351
41. Palestine AG, Nussenblatt RB, Gelato M. Therapy for human autoimmune uveitis with low-dose cyclosporin plus bromocriptine. Transplant Proc 1988;20(3 Suppl 4):131-135
42. Nussenblatt RB, Palestine AG, Chan CC, et al. Randomized, double-masked study of cyclosporin compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 1991;112(2):138-146
43. Deray GM, Benhmida M, Le Hoang P, et al. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporin therapy for idiopathic autoimmune uveitis. Ann Intern Med 1992;117(7):578-583
44. Tocci MJ, Sigal NH. Recent advances in the mechanism of action of cyclosporin and FK506. Curr Opin Nephrol Hypertens 1992;1(2):236-242
45. McAlister VC, Haddad E, Renouf E, et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006;6(7):1578-1585 (Pubitemid 43945797)
46. Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993;115(6):763-769 (Pubitemid 23171604)
47. Longoria J, Roberts RF, Marboe CC, et al. Sirolimus (rapamycin) potentiates cyclosporin in prevention of acute lung rejection. J Thorac Cardiovasc Surg 1999;117(4):714-718 (Pubitemid 29163075)
48. Nussenblatt RB, Coleman H, Jirawuthiworavong G, et al. The treatment of multifocal choroiditis associated choroidal neovascularization with sirolimus (rapamycin). Acta Ophthalmol Scand 2007;85(2):230-231 (Pubitemid 46243309)
49. Shanmuganathan VA, Casely EM, Raj D, et al. The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol 2005;89(6):666-669 (Pubitemid 40780569)
50. Martin DF, DeBarge LR, Nussenblatt RB, et al. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol 1995;154(2):922-927
51. Buech G, Bertelmann E, Pleyer U, et al. Formulation of sirolimus eye drops and corneal permeation studies. J Ocul Pharmacol Ther 2007;23(3):292-303 (Pubitemid 46986611)
52. Moro JA, Almenar L, Martinez-Dolz L, et al. Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation. Transplant Proc 2008;40(9):3034-3036
53. Anglade E, Aspeslet LJ, Weiss SL. A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin. Clin Ophthalmol 2008;2(4):693-702
54. Cunningham MA, Austin BA, Li Z, et al. LX211 (voclosporin) suppresses experimental uveitis and inhibits human T cells. Invest Ophthalmol Vis Sci 2009;50(1):249-255
55. Roda E. Uveitis treated with nitrogen mustard. Am J Ophthalmol 1952;35(1):114
56. Brubaker R, Font RL, Shepherd EM. Granulomatous sclerouveitis. Regression of ocular lesions with cyclophosphamide and prednisone. Arch Ophthalmol 1971;86(5):517-524
57. Fauci AS, Doppman JL, Wolff SM. Cyclophosphamide-induced remissions in advanced polyarteritis nodosa. Am J Med 1978;64(5):890-894
58. Fosdick WM, Parsons JL, Hill DF. Long-term cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum 1968;11(2):151-161
59. Hoang-Xaun T, Foster CS, Rice BA. Scleritis in relapsing polychondritis. Response to therapy. Ophthalmology 1990;97(7):892-898
60. Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314(10):614-619 (Pubitemid 16132725)
61. Durrani K, Papaliodis GN, Foster CS. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology 2004;111(5):960-965 (Pubitemid 38586692)
62. Miserocchi E, Baltatzis S, Ekong A, et al. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology 2002;109(1):137-142 (Pubitemid 34027437)
63. Mudun BA, Ergen A, Ipcioglu SU, et al. Short-term chlorambucil for refractory uveitis in Behcet's disease. Ocul Immunol Inflamm 2001;9(4):219-229 (Pubitemid 34286623)
64. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121(4):437-440 (Pubitemid 36427629)
65. Sfikakis PP. Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 2002;61(Suppl 2):ii51-3
66. Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001;44(6):1411-1415 (Pubitemid 32537541)
67. Fleischmann R, Iqbal I, Nadeshwar P, et al. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Saf 2002;25(3):173-197 (Pubitemid 34492938)
68. Diaz-Llopis M, García-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008;24(3):351-361 (Pubitemid 351733224)
69. Mushtaq B, Saeed T, Situnayake RD, et al. Adalimumab for sight-threatening uveitis in Behçet's disease. Eye (Lond) 2007;21(6):824-825 (Pubitemid 46909189)
70. Takase K, Ohno S, Ideguchi H, et al. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis. Rheumatol Int 2009. [Epub ahead of print]
71. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91(3):319-324 (Pubitemid 46586527)
72. Gallagher M, Quinones K, Cervantes-Castanẽda RA, et al. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007;91(10):1341-1344 (Pubitemid 47492870)
73. Tynjälä P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 2008;47(3):3397-3444 (Pubitemid 351267203)
74. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006;149(4):572-575 (Pubitemid 44468085)
75. Huynh N, Cervantes-Castaneda RA, Bhat P, et al. Biologic response modifier therapy for psoriatic ocular inflammatory disease. Ocul Immunol Inflamm 2008;16(3):89-93 (Pubitemid 351874121)
76. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65(12):1631-1634 (Pubitemid 44799677)
77. Rudwaleit M, Rødevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009;68(5):696-701
78. Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009;68(12):1863-1869
79. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7(3):251-259
80. Triolo G, Vadala M, Accardo-Palumbo A, et al. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease. Ann Rheum Dis 2002;61(6):560-561 (Pubitemid 34539106)
81. Breban M, Vignon E, Claudepierre P, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 2002;41(11):1280-1285 (Pubitemid 35363803)
82. Mangge H, Heinzl B, Grubbauer HM, et al. Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol Int 2003;23(5):258-261 (Pubitemid 37249139)
83. Gómez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48(8):2122-2127 (Pubitemid 36959191)
84. Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003;48(8):2224-2233 (Pubitemid 36959203)
85. Gallagher M, Quinones K, Cervantes-Castaneda RA, et al. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007;91(10):1341-1344 (Pubitemid 47492870)
86. Nussenblatt RB, Peterson JS, Foster CS, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 2005;112(5):764-770
87. Kobashigawa J, David K, Morris J, et al. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporin, and corticosteroids. Transplant Proc 2005;37(2):1333-1339 (Pubitemid 40590880)
88. Stratta RJ, Alloway RR, Lo A, et al. A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years. Transplant Proc 2005;37(8):3531-3534 (Pubitemid 41659943)
89. Tappeiner C, Heinz C, Specker C, Heiligenhaus A. Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 2007;39:184-186 (Pubitemid 46975985)
90. Onal S, Kazokoglu H, Koc A, et al. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis. Ocul Immunol Inflamm 2008;16(5):230-232
91. Sadreddini S, Noshad H, Molaeefard M, et al. Treatment of retinal vasculitis in Behcet's disease with rituximab. Mod Rheumatol 2008;18(3):306-308